Davenport & Co’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Davenport & Co’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,633	Closed	-$13K	–	1089
2022 Q1	$13K	Sell	2,633 -1,767	-40%	-$11.1K	﹤0.01%	1059
2021 Q4	$25K	Sell	4,400 -20,317	-82%	-$173K	﹤0.01%	1071
2021 Q3	$274K	Sell	24,717 -2,056	-8%	-$25.8K	﹤0.01%	891
2021 Q2	$454K	Buy	26,773 +153	+0.6%	+$2.9K	﹤0.01%	675
2021 Q1	$699K	Buy	26,620 +6,933	+35%	+$315K	0.01%	465
2020 Q4	$712K	Buy	19,687 +8,534	+77%	+$309K	0.01%	438
2020 Q3	$395K	Buy	11,153 +7,106	+176%	+$309K	﹤0.01%	515
2020 Q2	$172K	Sell	4,047 -1,250	-24%	-$84.3K	﹤0.01%	661
2020 Q1	$423K	Buy	5,297 +2,957	+126%	+$237K	0.01%	446
2019 Q4	$217K	Buy	+2,340	New	+$197K	﹤0.01%	658

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Davenport & Co's EVFM Position: Q2 2022 in Review

Davenport & Co sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 2,633 shares — an estimated $13K sold.

Davenport & Co first reported a position in EVFM in Q4 2019 and held it in 10 quarters. The position peaked at $712K in Q4 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

Davenport & Co reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Davenport & Co sold 2,633 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $13K.
Davenport & Co first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
Davenport & Co's Evofem Biosciences, Inc. Common Stock position peaked at $712K in Q4 2020.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Davenport & Co's 13F filing for Q2 2022, filed 18 Jul 2022.